Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) issued its earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04, FiscalAI reports.
Allarity Therapeutics Trading Up 0.7%
Shares of NASDAQ:ALLR traded up $0.01 during mid-day trading on Friday, hitting $1.37. 45,504 shares of the company traded hands, compared to its average volume of 72,726. The stock has a 50-day moving average price of $1.31 and a two-hundred day moving average price of $1.26. Allarity Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.35. The stock has a market cap of $21.80 million, a P/E ratio of -1.90 and a beta of 0.51.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on ALLR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Friday, July 17th. Ascendiant Capital Markets lifted their price target on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research note on Monday, June 8th. Finally, Wall Street Zen raised shares of Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.25.
Institutional Trading of Allarity Therapeutics
Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Allarity Therapeutics during the second quarter valued at about $27,000. XTX Topco Ltd purchased a new stake in Allarity Therapeutics in the 4th quarter valued at about $36,000. Geode Capital Management LLC lifted its position in shares of Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Allarity Therapeutics in the 4th quarter worth approximately $133,000. Finally, Citadel Advisors LLC bought a new position in shares of Allarity Therapeutics in the third quarter valued at approximately $149,000. Institutional investors own 11.53% of the company’s stock.
Allarity Therapeutics Company Profile
Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.
The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.
Read More
- Five stocks we like better than Allarity Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
